QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biofrontera-completes-treatment-phase-in-phase-3-trial-of-ameluz-for-actinic-keratosis-on-body-supplemental-new-drug-application-planned-for-submission-in-q2-2026

All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in ...

 biofrontera-completes-final-patient-visit-in-phase-2b-acne-trial-top-line-results-expected-q1-2026-plans-fda-discussion-for-phase-3-in-q3

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in ...

 biofrontera-q2-eps-057-misses-042-estimate-sales-903m-beat-830m-estimate

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42)...

 biofrontera-inc-acquires-all-us-rights-to-ameluz-and-rhodoled-from-former-parent-co-biofrontera-ag-coupled-with-11m-financing-led-bt-existing-investors-under-new-agreement-effective-royalty-rate-paid-by-co-will-be-reduced-to-12-of-net-sales

Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Applicati...

 biofrontera-confirms-talks-with-biofrontera-ag-on-potential-merger-or-deal-restructuring-to-lower-us-product-costs

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic th...

 biofronteras-propylene-glycol-free-ameluz-formulation-receives-fda-orange-book-listing-following-april-2025-patent-approval-extending-protection-through-2043

Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through ...

 benchmark-maintains-buy-on-biofrontera-lowers-price-target-to-275

Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $7 to $2.75.

 biofrontera-receives-patent-approval-for-updated-formulation-of-ameluz-nanoemulsion-gel-without-propylene-glycol-through-to-december-2043

Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to Dec...

 biofrontera-q4-2024-gaap-eps-019-beats-024-estimate-sales-1256m-beat-1150m-estimate

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.24) b...

 biofrontera-fy-2024-gaap-eps-322-may-not-be-comparable-to-085-estimate-sales-3732m-miss-4706m-estimate

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.85)...

 biofrontera-completes-patient-enrollment-of-phase-3-study-of-ameluz-topical-gel-10-for-actinic-keratoses-on-extremities

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT tre...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION